Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Cited by (1,006)

Items 601–700 of 1,006

1. Autophagy Control by the VEGF-C/NRP-2 Axis in Cancer and Its Implication for Treatment Resistance
   Marissa J. Stanton, Samikshan Dutta, Heyu Zhang, Navatha S. Polavaram, Alexey A. Leontovich, Pia Hönscheid, Frank A. Sinicrope, Donald J. Tindall, Michael H. Muders, Kaustubh Datta · 2012 · Cancer Research
2. Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer
   Khalid Saeed, Vesa Rahkama, Samuli Eldfors, Dmitry Bychkov, John Patrick Mpindi, Bhagwan Yadav, Lassi Paavolainen, Tero A. Aittokallio, Caroline Akemi Heckman, Krister Wennerberg et al. · 2016 · European Urology
3. Phase II study of docetaxel re‐treatment in docetaxel‐pretreated castration‐resistant prostate cancer
   Giuseppe Di Lorenzo, Carlo Buonerba, Adriana Faiella, Pasquale Rescigno, Mimma Rizzo, Riccardo Autorino B, Sisto Perdonà, Ferdinando Riccardi, Sarah Scagliorini, Florinda Scognamiglio et al. · 2010 · British Journal of Urology
4. Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate
   François Rozet, Christophe Hennequin, Jean‐Baptiste Beauval, Philippe Beuzeboc, Luc Cormier, Gaëlle Fromont, Pierre Mongiat-Artus, Guillaume Ploussard, Romain Mathiéu, L. Brureau et al. · 2018 · The French Journal of Urology
5. Off-label use of anticancer drugs
   Dominique Levêque · 2008 · The Lancet Oncology
6. Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
   Harm Westdorp, Annette E. Sköld, Berit A. Snijer, Sebastian Franik, Sasja F. Mulder, Pierre P Major, Ronan Foley, Winald R. Gerritsen, I. Jolanda M. de Vries · 2014 · Frontiers in Immunology
7. Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
   Andrea Fontana, Luca Galli, Anna Fioravanti, Paola Orlandi, Costanza Galli, Lorenza Maria Landi, Simona Bursi, Giacomo Allegrini, Eloise Fontana, Roberta Di Marsico et al. · 2009 · Clinical Cancer Research
8. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
   Satoshi Wada, Christopher Mitchell Jackson, Kiyoshi Yoshimura, Hung‐Rong Yen, Derese Getnet, Timothy J Harris, Monica V. Goldberg, Tullia Carmela Bruno, Joseph F. Grosso, Nicholas M. Durham et al. · 2013 · Journal of Translational Medicine
9. Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone
   Donna Lynn Berry, Carol M. Moinpour, Caroline S. Jiang, Donna Pauler Ankerst, Daniel Peter Petrylak, Lynne V. Vinson, Primo N. Lara, Sharon Jones, Mary Ellen Taplin, Patrick A. Burch et al. · 2006 · Journal of Clinical Oncology
10. Docetaxel Plus Prednisolone for the Treatment of Metastatic Hormone-refractory Prostate Cancer: A Multicenter Phase II Trial in Japan
    Seiji Naito, Tadashi Tsukamoto, Hirofumi Koga, Toru Harabayashi, Yoshiteru Sumiyoshi, Senji Hoshi, Hideyuki Akaza · 2008 · Japanese Journal of Clinical Oncology
11. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both
    Nicholas David James, Sarah J. Pirrie, Ann Pope, Darren Barton, Lazaros Andronis, Ilias Goranitis, Stuart I. Collins, Adam Daunton, Duncan B. McLaren, Joe M. O’Sullivan et al. · 2016 · JAMA Oncology
12. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone
    Penelope Dawn Ottewell, Ning Wang, J. Meek, C. Anne Fowles, Peter Ian Croucher, Colby L. Eaton, Ingunn Holen · 2014 · Endocrine Related Cancer
13. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
    Yohann Loriot, Christophe Massard, Marine Gross‐Goupil, Mario Di Palma, Bernard J. Escudier, Alberto Bossi, Anne Chauchereau, Karim S. Fizazi · 2010 · European Journal of Cancer
14. Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy
    Peter Mulders, Arturo Molina, Michael Marberger, Fred Saad C, Celestia S. Higano, Kim N. Chi, Jinhui Li, Thian San Kheoh, Christopher M. Haqq, Karim S. Fizazi · 2013 · European Urology
15. Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
    Yusuke Imamura, Marianne D. Sadar · 2016 · International Journal of Urology
16. Increased expression of class III β-tubulin in castration-resistant human prostate cancer
    Stéphane Terry, Guillaume Ploussard, Yves Allory, Nathalie Nicolaı̈ew, Florence Boissière‐Michot, P Maillé, Laurence Kheuang, Estelle Coppolani, A Ali, Frédéric Bibeau et al. · 2009 · British Journal of Cancer
17. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
    Stephen John Harland, John Nicholas Staffurth, Arturo Molina, Yanni Hao, Dennis D. Gagnon, Cora Nanette Sternberg, David F Cella, Karim S. Fizazi, Christopher J. Logothetis, Thian San Kheoh et al. · 2013 · European Journal of Cancer
18. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases
    Bertrand F. TOMBAL, Afshin Rezazadeh, Patrick Therasse, Paul J. Van Cangh, Bruno Vande Berg, Frederic E. Lecouvet · 2005 · The Prostate
19. Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
    Masuo Yamaoka, Takahito Hara, Masami Kusaka · 2010 · Clinical Cancer Research
20. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
    Chowdhury, Simon, Bjartell, Anders, Lumen, Nicolaas, Maroto, Pablo, Paiss, Thomas, Gomez-Veiga, Francisco, Birtle, Alison, Kramer, Gero, Kalinka, Ewa, Spaëth, Dominique et al. · 2020 · Targeted Oncology
21. Insights into Chemoresistance of Prostate Cancer
    Wei Zhang, Yan Meng, Na Liu, Xiaofei Wen, Tao Yang · 2015 · International Journal of Biological Sciences
22. [18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results
    Francesco Pasqualetti, Marco Panichi, A. Sainato, Fabrizio Matteucci, Luca Galli, Paola Cocuzza, Patrizia Ferrazza, Gabriele Coraggio, Giuseppe Pasqualetti, Lisa Derosa et al. · 2016 · Radiation Oncology
23. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone
    Dana E. Rathkopf, Emmanuel S. Antonarakis, Neal D. Shore, Ronald F. Tutrone Jr., Joshi J. Alumkal, Charles J. Ryan, Mansoor Noorali Saleh, Ralph J. Hauke, Rajesh R. Bandekar, Edna Chow Maneval et al. · 2017 · Clinical Cancer Research
24. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
    Daria Handkiewicz-Junak, Thorsten Dirk Poeppel, Lisa Bodei, Cumali Aktolun, Samer Ezziddin, Francesco Giammarile, Roberto Carlos Delgado Bolton, Michael Gabriel · 2018 · European Journal of Nuclear Medicine and Molecular Imaging
25. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways
    André N. Vis, Fritz H. Schröder · 2009 · British Journal of Urology
26. Exosome-derived microRNAs contribute to prostate cancer chemoresistance
    Jing Li, Xin Yang, Hao Guan, Atsushi Mizokami, Evan T. Keller, Xiaozhen Xu, Xia Liu, Jiyong Tan, Longyuan Hu, Yi Lü et al. · 2016 · International Journal of Oncology
27. Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer
    Qi Wang, Heba A Alshaker, Torsten Böhler, Shyam Srivats, Yimin Chao, Colin Cooper, Dmitri Pchejetski · 2017 · Scientific Reports
28. Targeting TCTP as a New Therapeutic Strategy in Castration-resistant Prostate Cancer
    Virginie Baylot, Maria Katsogiannou, Claudia Andrieu, David Taïeb, Julie Acunzo, Sophie Giusiano, Ladan Fazli, Martin Edwin Gleave, Carmen Garrido, Palma Rocchi · 2012 · Molecular Therapy
29. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells
    Yun Luo, You Ling, Wusheng Guo, Jun Pang, Weipeng Liu, Youqiang Fang, Xinqiao Wen, Kun Wei, Xin Gao · 2010 · Journal of Controlled Release
30. The evolution of chemotherapy for the treatment of prostate cancer
    David I. Quinn, Howard Mark Sandler, Lisa Glen Horvath, Amir Goldkorn, James Andrew Eastham · 2017 · Annals of Oncology
31. A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer.
    Elisabeth I. Heath, Lance K. Heilbrun, Jing Li, Ulka N. Vaishampayan, Felicity W. K. Harper, Pam Pemberton, Fazlul H. Sarkar · 2010 · PubMed Central
32. Satraplatin: an orally available platinum analog for the treatment of cancer
    Hak Choy · 2006 · Expert Review of Anticancer Therapy
33. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles
    Gero Kramer, S Schwarz, Mirja Hägg, Aleksandra Mandic Havelka, Stig T. Linder · 2006 · British Journal of Cancer
34. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
    Mitchell Eric Gross, Celestia S. Higano, Allan J. Pantuck, Olga O. Castellanos, Erica Green, KOO N. NGUYEN, David B. Agus · 2007 · BMC Cancer
35. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
    Yohann Loriot, Christophe Massard, Marine Gross‐Goupil, Mario Di Palma, Bernard J. Escudier, A. Bossi, Karim S. Fizazi · 2009 · Annals of Oncology
36. Expanding Treatment Options for Metastatic Prostate Cancer
    Emmanuel S. Antonarakis, Mario A. Eisenberger · 2011 · New England Journal of Medicine
37. Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines
    Ravi Amrit Madan, Marijo Bilušić, Christopher Ryan Heery, Jeffrey Schlom, James L. Gulley · 2012 · Seminars in Oncology
38. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)
    Simon J. Crabb, Gareth Owen Griffiths, Ellice Marwood, Denise Dunkley, Nichola Downs, Karen Martin, Michelle Light, Josh Northey, Sam A. Wilding, Amy L. Whitehead et al. · 2020 · Journal of Clinical Oncology
39. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
    Dana E. Rathkopf, Manish R. Patel, Atish Dipankar Choudhury, Drew Warren Rasco, Nehal J. Lakhani, Jessica E. Hawley, Sandy Srinivas, Ana M. Aparicio, Vivek Narayan, Karie D. Runcie et al. · 2024 · Annals of Oncology
40. Role of the EpCAM (CD326) in prostate cancer metastasis and progression
    Jie Ni, Paul J. Cozzi, Wei Duan, Sarah L. Shigdar, Peter Graham, Kearsley H. John, Yong Li · 2012 · Cancer and Metastasis Reviews
41. 123I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy
    Shawn Hillier, Ashley M. Kern, Kevin P. Maresca, John C. Marquis, William C. Eckelman, John L. Joyal, John W. Babich · 2011 · Journal of Nuclear Medicine
42. Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
    Brandon Bumbaca, Wěi Li · 2018 · Acta Pharmaceutica Sinica B
43. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer
    Francesco Crea, Maria A. Duhagon Serrat, Elaine M. Hurt, Suneetha B. Thomas, Romano Danesi, William L. Farrar · 2010 · International Journal of Cancer
44. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer
    Jinge Zhao, Shu Ning, Wei Lou, Joy C. Yang, Cameron M. Armstrong, Alan Paul Lombard, Leandro Salati D'Abronzo, Christopher P. Evans, Allen C. Gao, Chengfei Liu · 2020 · Molecular Cancer Therapeutics
45. Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
    Andrew J. Armstrong, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Zelig Szmulewitz, Daniel Costin Danila, Patrick N Healy, Monika Anand, William R. Berry, Tian Zhang et al. · 2020 · JCO Precision Oncology
46. YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer
    Hsiu-Chi Lee, Chien-Hui Ou, Yun‐Chen Huang, Pei‐Chi Hou, Chad J. Creighton, Yi-Syuan Lin, Che‐Yuan Hu, Shih‐Chieh Lin · 2021 · Oncogene
47. Cross-resistance and drug sequence in prostate cancer
    Stefan A.J. Buck, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ronald de Wit, Robert J. van Soest · 2021 · Drug Resistance Updates
48. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
    Evan Y. Yu, Michael Paul Kolinsky, William R. Berry, Margitta M. Retz, Loı̈c Mourey, Josep Maria Piulats, Leonard Joseph Appleman, Emanuela Romano, Gwénaëlle Gravis, Howard Gurney et al. · 2022 · European Urology
49. Vaccines as treatments for prostate cancer
    Ichwaku Rastogi, Anusha Muralidhar, Douglas G. McNeel · 2023 · Nature Reviews Urology
50. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
    Orazio Caffo, Ugo De Giorgi, Lucia Fratino, Daniele Alesini, Vittorina Zagonel, Gaetano Facchini, Donatello Gasparro, Cinzia Ortega, Marcello Tucci, Francesco Verderame et al. · 2014 · European Urology
51. Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells
    Eleftheria Tsakalozou, Allison M. Eckman, Younsoo Bae · 2012 · Biochemistry Research International
52. In Vitro and In Vivo Prostate Cancer Metastasis and Chemoresistance Can Be Modulated by Expression of either CD44 or CD147
    Jingli Hao, Michele C. Madigan, Aparajita Khatri, Carl Andrew Power, Tzong‐Tyng Hung, Julia Beretov, Lei Chang, Weiwei Xiao, Paul J. Cozzi, Peter Graham et al. · 2012 · PLoS ONE
53. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials
    Anthony Victor D'Amico, Ming‐Hui Chen, Mário de Castro, Marian J. Loffredo, David S. Lamb, Allison Steigler, Philip W. Kantoff, James William Denham · 2011 · The Lancet Oncology
54. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring
    Xi-De Wang, Karen A. Reeves, Feng Roger Luo, Lian Xu, Francis Y. Lee, Edwin A. Clark, Fei Huang · 2007 · Genome biology
55. Garlic-DerivedS-allylmercaptocysteine Is a NovelIn vivoAntimetastatic Agent for Androgen-Independent Prostate Cancer
    Edward W. Howard, Ming‐Tat Ling, Chee Wai Chua, Hiu Wing Cheung, Xianghong Wang, Yong Chuan Wong · 2007 · Clinical Cancer Research
56. Combined In vivo Effect of A12, a Type 1 Insulin-Like Growth Factor Receptor Antibody, and Docetaxel against Prostate Cancer Tumors
    Jennifer D. Wu, Kathy H Haugk, Ilsa M. Coleman, Lillie B. Woodke, Robert L. Vessella, Peter S. Nelson, Bruce Montgomery, Dale L. Ludwig, Stephen R. Plymate · 2006 · Clinical Cancer Research
57. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)
    ICECaP Working Group · 2015 · JNCI Journal of the National Cancer Institute
58. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer
    Emmanuel S. Antonarakis, Scott T. Tagawa, Giuseppe Galletti, Daniel Worroll, Karla V. Ballman, Marie Vanhuyse, Guru Sonpavde, Scott A. North, Costantine Albany, Che‐Kai Tsao et al. · 2017 · Journal of Clinical Oncology
59. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
    Vincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, Daniel Wetterskog, Samanta Salvi, Giorgia Gurioli, Emanuela Scarpi, Elena Castro, Mercedes Marín‐Aguilera, Cristian Lolli et al. · 2018 · European Urology
60. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer
    Tian Zhang, Lawrence Ivan Karsh, Michael J. Nissenblatt, Steven E. Canfield · 2019 · Clinical Genitourinary Cancer
61. Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT / mTOR pathway in prostate cancer
    Hongzhuang Wen, Changbao Qu, Zhu Wang, Haitao Gao, Wuyao Liu, Hu Wang, Hao Sun, Junfei Gu, Zhan Yang, Xiaolu Wang · 2023 · The FASEB Journal
62. Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells
    Manuel Colucci, Sara Zumerle, Silvia Bressan, Federico Gianfanti, Martina Troiani, Aurora Valdata, Mariantonietta D’Ambrosio, Emiliano Pasquini, Angelica Varesi, Francesca Cogo et al. · 2024 · Cancer Cell
63. CYP17A1 inhibitors in castration-resistant prostate cancer
    Lissette Gomez, Jason Ronald Kovac, Dolores J. Lamb · 2015 · Steroids
64. Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
    Julie Nicole Graff, Erin D. Chamberlain · 2014 · Core evidence
65. A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
    Sarah Patricia Blagden, L. Rhoda Molife, A Seebaran, Miranda Payne, Alison H. M. Reid, Andrew S. Protheroe, Lakshmi Vasist, Daphne D. Williams, Chester L. Bowen, Steven J. Kathman et al. · 2008 · British Journal of Cancer
66. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis
    Robert E. Miller, Martine P. Roudier, Jon C. Jones, Allison P. Armstrong, Jude R. Canon, William C. Dougall · 2008 · Molecular Cancer Therapeutics
67. Association of theCYP1B1*3allele with survival in patients with prostate cancer receiving docetaxel
    Tristan M. Sissung, Romano Danesi, Douglas K. Price, Seth M. Steinberg, Ronald de Wit, Muhammad Zahid, Nilesh W. Gaikwad, Ercole L. Cavalieri, William L. Dahut, Dan L. Sackett et al. · 2008 · Molecular Cancer Therapeutics
68. Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases
    Grant Chavin, Yuri M. Sheinin, Paul L. Crispen, Stephen Anthony Boorjian, Timothy J. Roth, Laureano J. Rangel, Michael L. Blute, Thomas J. Sebo, D. Tindall, Eugene D. Kwon et al. · 2009 · Clinical Cancer Research
69. Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer
    Waldemar Wilczak, Corinna Wittmer, Till Sebastian Clauditz, Sarah Jane Pauline Minner, Stefan A. Steurer, Franziska Büscheck, Till Krech, Maximilian Lennartz, Luisa Harms, Diane Leleu et al. · 2018 · European Urology
70. mCRPC Patients Receiving ²²⁵ Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
    Sathekge, Mike, Bruchertseifer, Frank, Vorster, Mariza, Lawal, Ismaheel O., Knoesen, Otto, Mahapane, Johncy, Davis, Cindy, Mdlophane, Amanda, Maes, Alex, Mokoala, Kgomotso et al. · 2022 · Journal of Nuclear Medicine
71. C11-Acetate and F-18 FDG PET for Men With Prostate Cancer Bone Metastases
    Evan Y. Yu, Mark Muzi, Joy A. Hackenbracht, Brian B. Rezvani, Jeanne M. Link, Bruce Montgomery, Celestia S. Higano, Janet F. Eary, David A. Mankoff · 2011 · Clinical Nuclear Medicine
72. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
    Kenrick Ng, Shievon Smith, Jonathan Shamash · 2020 · Oncology and Therapy
73. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
    Keiichiro Mori, Hadi Mostafaei, Benjamin Pradère, Reza Sari Motlagh, Fahad Quhal, Ekaterina Laukhtina, Victor M. Schuettfort, Mohammad M. Abufaraj, Pierre I. Karakiewicz, Takahiro Kimura et al. · 2020 · International Journal of Clinical Oncology
74. Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
    Koji Hatano, Norio Nonomura · 2023 · The World Journal of Men s Health
75. Identification and Functional Validation of Reciprocal microRNA–mRNA Pairings in African American Prostate Cancer Disparities
    Bi‐Dar Wang, Kristin Ceniccola, Qi Yang, Ramez I. Andrawis, Vyomesh Patel, Youngmi Ji, Johng Sik Rhim, Jacqueline Olender, Anastas S. Popratiloff, Patricia S. Latham et al. · 2015 · Clinical Cancer Research
76. The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development
    Paul Gettys Corn · 2012 · Cancer Management and Research
77. Novel targeted therapeutics for metastatic castration-resistant prostate cancer
    Emmanuel S. Antonarakis, Michael Anthony Carducci, Mario A. Eisenberger · 2009 · Cancer Letters
78. Phase I/II Study of 19-nor-1α-25-Dihydroxyvitamin D2 (Paricalcitol) in Advanced, Androgen-Insensitive Prostate Cancer
    Gary G. Schwartz, M. Craig Hall, Diana Stindt, Suzanne E. Patton, James F. Lovato, Frank M. Torti · 2005 · Clinical Cancer Research
79. Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer
    Boštjan Šeruga, Ian F. Tannock · 2011 · Journal of Clinical Oncology
80. Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer
    Andrea Borghese Apolo, Liza Lindenberg, Joanna H. Shih, Esther Mena, Joseph W. Kim, Jong Chul Park, Anna Alikhani, Yolanda L. McKinney, Juanita Weaver, Barış Türkbey et al. · 2016 · Journal of Nuclear Medicine
81. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
    Mamta Parikh, Chengfei Liu, Chun‐Yi Wu, Christopher P. Evans, Marc Dall’Era, Daniel Robles, Primo N. Lara, Neeraj Agarwal, Allen C. Gao, Chong-xian Pan · 2021 · Scientific Reports
82. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition
    Hiroki Tamaki, Nanae Harashima, Miho Hiraki, Naoko Arichi, Nobuhiro Nishimura, Hiroaki Shiina, Kohji Naora, Mamoru Harada · 2014 · Oncotarget
83. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization
    Hui Yi Xue, Ho Lun Wong · 2011 · Biomaterials
84. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials
    Andreas S. Varkaris, Paul Gettys Corn, Sanchaika Gaur, Farshid Dayyani, Christopher J. Logothetis, Gary E. Gallick · 2011 · Expert Opinion on Investigational Drugs
85. Metabolic control analysis indicates a change of strategy in the treatment of cancer
    Rafael Moreno‐Sánchez, Emma Saavedra, Sara Rodríguez‐Enríquez, Juan Carlos Gallardo‐Pérez, Héctor Quezada, Hans Victor Westerhoff · 2010 · Mitochondrion
86. Cancer de la prostate
    Philippe Beuzeboc, François Cornud, Pascal Eschwège, N. Gaschignard, Pascale Grosclaude, Christophe Hennequin, P. Maingon, Vincent Molinié, Pierre Mongiat-Artus, Jean-Luc Moreau et al. · 2007 · The French Journal of Urology
87. The current role of chemotherapy in metastatic hormone-refractory prostate cancer
    Daniel Peter Petrylak · 2005 · Urology
88. Fractionation of high molecular weight tannins in grape seed extract and identification of procyanidin B2-3,3′-di-O-gallate as a major active constituent causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells
    Chapla Agarwal, Veluri Ravikanth, Manjinder Kaur, Shen‐Chieh Chou, John A. Thompson, Rajesh Agarwal · 2007 · Carcinogenesis
89. Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer
    Punam H Patel, Denise R Kockler · 2007 · Annals of Pharmacotherapy
90. Liver metastases in prostate carcinoma: clinical characteristics and outcome
    Damien Pouessel, Blandine Gallet, Frédéric Bibeau, C. Avancès, François Iborra, Pierre Sénesse, Stéphane Culine · 2006 · British Journal of Urology
91. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial
    Anne M. Horgan, Boštjan Šeruga, Gregory R. Pond, Shabbir M.H. Alibhai, Eitan Amir, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock · 2014 · Journal of Geriatric Oncology
92. Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer
    Neeraj Agarwal, Guru Sonpavde, Cora Nanette Sternberg · 2011 · European Urology
93. Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer
    Ramachandran Venkitaraman, Karen Thomas, Robert Anthony Huddart, Alan Horwich, David Paul Dearnaley, Chris C. Parker · 2007 · British Journal of Urology
94. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy
    Xiang Liu, Joseph Cheng, Lorianne S. Turner, Saeed N. Elojeimy, Thomas Hendrix Beckham, Alicja E. Bielawska, Thomas E. Keane, Yusuf Awni Hannun, James Scott Norris · 2009 · Expert Opinion on Therapeutic Targets
95. A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
    Axel Heidenreich, Sudhir Kumar Rawal, K. Szkarlat, Natalia Viktorovna Bogdanova, Luc Yves Dirix, Arnulf Stenzl, Manfred Welslau, G. Wang, Fitzroy W. Dawkins, Carla J. de Boer et al. · 2012 · Annals of Oncology
96. Prostate-Specific Membrane Antigen-Based Therapeutics
    Naveed H. Akhtar, Orrin Pail, Ankeeta Saran, Lauren Tyrell, Scott T. Tagawa · 2011 · Advances in Urology
97. Integrative Molecular Profiling Reveals Asparagine Synthetase Is a Target in Castration-Resistant Prostate Cancer
    Kanishka Sircar, Heng Huang, Limei Hu, David E. Cogdell, Jasreman Dhillon, Vassiliki Tzelepi, Eleni Efstathiou, Ismaël Hervé Koumakpayi, Fred Saad C, Dijun Luo et al. · 2012 · American Journal Of Pathology
98. Impact ofIGF-IandCYP19Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer
    Norihiko Tsuchiya, Lizhong Wang, Hiroyoshi Suzuki, Takehiko Segawa, Hisami Fukuda, Shintaro Narita, Masaki Shimbo, Toshiyuki Kamoto, Kenji Mitsumori, Tomohiko Ichikawa et al. · 2006 · Journal of Clinical Oncology
99. Androgen–glucocorticoid interactions in the era of novel prostate cancer therapy
    Sujata Narayanan, Sandy Srinivas, David Feldman · 2015 · Nature Reviews Urology
100. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
     Johann Sebastian De Bono, Matthew Raymond Smith, Fred Saad C, Dana E. Rathkopf, Peter Mulders, Eric Jay Small, Neal D. Shore, Karim S. Fizazi, Peter De Porre, Thian San Kheoh et al. · 2016 · European Urology